Home / Health / Medicare Enrollment: Don't Miss Your Cancer Care Window
Medicare Enrollment: Don't Miss Your Cancer Care Window
7 Apr
Summary
- A seven-month enrollment window is critical for cancer care coverage.
- AI may streamline Medicare reviews, risking denial rates and delays.
- Oral cancer therapies are expensive, requiring Part D for coverage.
For those turning 65 in 2026, a critical seven-month enrollment window beginning three months before and ending three months after their birthday is vital for securing optimal cancer care. This period allows enrollment in original Medicare with supplemental coverage (Medigap) and Part D without medical underwriting.
Failure to enroll during this time can lead to coverage denials or increased rates based on health status, precisely when protection is most needed. This is particularly important as the future of cancer treatment involves expensive oral medications, often exceeding $10,000 monthly.
Meanwhile, a new AI-assisted program, the Wasteful and Inappropriate Service Reduction Model (WISeR), began in six states on January 1, 2026. While intended to improve efficiency in prior authorization reviews, concerns exist that algorithmic oversight could increase denial rates and delay care, echoing problems previously observed in Medicare Advantage.
These delays can have severe consequences, as demonstrated by a Texas retiree whose biopsy approval was delayed, allowing his cancer to become terminal. Between 2019 and 2023, over 80% of Medicare Advantage appeals were successful, but only after significant patient struggles and harmful delays.
